Event info
Date:23 Aug
Venue:Maersk Tower, Copenhagen

Academic Drug Discovery

Welcome to Academic Drug Discovery – how to secure that preclinical findings reach the patients

The Medicon Valley universities have many research activities within early drug discovery and they offer a wide range of know-how and research within new therapeutic goals and new and innovative methods to develop drugs. These activities can support drug development not only at the universities but also at other life-science institutions/companies in the region. However, there is currently no clear formalized initiative between academic preclinical drug discovery, clinical trials and the region’s life science industry. How can we ensure maximum exchange between preclinical research findings, related knowledge, and technologies from the academia and the life-science industry and thereby facilitate the progression of novel drug candidates so that they reach all the way to patients and create social benefits?

University of Copenhagen, Lund University, and Medicon Valley Alliance invite you to Academic Drug Discovery – how to secure that preclinical findings reach the patients:

Date: 23 August 2018
Time: 8.30 – 16.30
Venue: Nielsine Nielsen auditorium, The Maersk Tower, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N
Cost: Free of charge for MVA members

Sign up – This event is fully booked. Please sign up to be included on our waiting list

By strengthening preclinical drug discovery, increasing the number of academic clinical studies, and optimizing trial designs by e.g. including companion diagnostics, important prerequisites to ensure continued growth of the Swedish-Danish life science sector are created. This event intends to serve as a first step in establishing a more effective regional platform for academic/clinical drug research.



Registration and networking


Welcome and introduction
Petter Hartman, CEO, Medicon Valley Alliance
Trine Winterø, Vice-Dean for Innovation and External Relations, University of Copenhagen
Nils Brünner, Professor emeritus & CEO, Scandion Oncology
Roland Andersson, Professor, Lund University


NEXT – a public – private partnership to attract clinical trials to Denmark – how do we
do and what is needed to ensure attractiveness?
Britta Smedegaard, Project Director, NEXT


The patent perspective – Dos and Don’ts
Jens Viktor Nørgaard, Partner & European Patent Attorney, HØIBERG P/S


The enzyme MTH1 as a novel target in cancer therapy – a journey from the lab bench to first-in-human clinical trial
Ulrika Warpman Berglund, PhD, Project Manager, Karolinska Institutet, SciLifeLab


Fish and  Grasshoppers in the Service of MANkind
Roger Olsson, Professor of  Chemical Biology, Lund University


Coffee and networking


From academic discoverers to biotech
Kristian Strømgaard, Professor, University of Copenhagen


Drug discovery in Immuno-Oncology
Peter Ellmark, Vice President Discovery, Alligator Bioscience AB


From brain research to applied science – How do we transform great academic ideas into drugs
Anders Gersel Pedersen, Executive Vice President, H. Lundbeck A/S


BioInnovation Institute: Helping life science entrepreneurs to bring science out of the
lab and into the economy
Thomas Nagy, Director, BioInnovation Institute


Lunch & networking


Workshop: How to create a formalized platform for academic drug discovery including infrastructure and know-how
All attendees


Summary of workshop and next step
Nils Brünner, Professor emeritus & CEO, Scandion Oncology


Panel discussion


Refreshments and networking

Deadline for registration is 17th of August, 2018.

For more information please contact Senior Project Manager Helen Pettersson: hp@mva.org

In collaboration

logo uni_copenhagen logo LU

mva logo